Lung Cancer | Specialty

Recommended Mutation Testing in Lung Cancer

November 20th 2014

Dr. Herbst Discusses the State of Immunotherapy in Lung Cancer

November 18th 2014

Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, discusses the state of immunotherapy in lung cancer.

Ceritinib Effective in Patients With Brain Metastases

November 15th 2014

The next-generation ALK inhibitor ceritinib showed clinically significant antitumor activity in patients with ALK-rearranged NSCLC, including those with brain metastases.

CMS Will Cover Screening for Lung Cancer With LDCT

November 12th 2014

The Centers for Medicare & Medicaid Services (CMS) announced that the agency plans to cover lung cancer screening using low-dose computed tomography (LDCT) for certain former and current smokers, a decision that could affect an estimated 4 million people.

Dr. Felip Discusses Ceritinib's Response in ALK+ NSCLC

November 12th 2014

Enriqueta Felip, MD, PhD, medical oncologist, Vall d'Hebron University Hospital, Barcelona, Spain, discusses the efficacy and safety of ceritinib in patients with ALK-positive non-small cell lung cancer (NSCLC).

Dr. Chu Discusses CNS Penetration of Ceritinib

November 12th 2014

Quincy Chu, MD, University of Alberta, Cross Cancer Institute, Edmonton, Alberta, discusses the ability of ceritinib to penetrate the CNS.

Immunotherapies Continue to Impress in NSCLC Trials With Several Forecast for Approval

November 10th 2014

Roy S. Herbst, MD, PhD, led some of the first trials of gefitinib, the EGFR inhibitor that helped introduce targeted therapies of this important mutation into the treatment landscape of non–small cell lung cancer.

With Limited Progression, Maintaining TKI Regimen Often Optimal Approach in Lung Cancer

November 10th 2014

How should oncologists respond when initial treatment of EGFR-mutant or ALK-positive lung cancer with a tyrosine kinase inhibitor (TKI) no longer prevents all disease progression?

Lung Cancer Treatment on Brink of New Molecular Era

November 10th 2014

Although testing for EGFR mutations and ALK rearrangements in patients with NSCLC has become widespread, the time has come to translate into clinical practice next-generation sequencing assays that provide exponentially more information about tumor biology.

Dr. Levy Discusses Recent Updates in Immunotherapy for Lung Cancer

November 10th 2014

Benjamin P. Levy, MD, director, Thoracic Medical Oncology, Mount Sinai Beth Israel, associate director, Cancer Clinical Trials Office, Mount Sinai Hospital, Mt. Sinai School of Medicine, discusses new data on immunotherapy for lung cancer.

Dr. Arcila on the Benefits of New Molecular Diagnostic Platforms for the Treatment of Lung Cancer

November 10th 2014

Maria E. Arcila, MD, acting director, Diagnostic Molecular Pathology Laboratory, Memorial Sloan Kettering Cancer Center, discusses the benefits of new molecular diagnostic platforms for the treatment of lung cancer.

Dr. Lynch Discusses Resistance to EGFR TKIs in Lung Cancer

November 8th 2014

Thomas J. Lynch, MD, from the Yale Cancer Center, explains how resistance occurs when treating lung cancer patients with EGFR TKIs.

PER Conference Features Expert Views on Lung Cancer Advances

November 7th 2014

Lung cancer experts provided insights into recent developments in the treatment of the disease, covering topics ranging from resistance to targeted therapies to immunotherapy agents under study, during the 9th Annual New York Lung Cancer Symposium in New York City.

Dr. Papadimitrakopoulou Provides an Update on Pembrolizumab for Lung Cancer

November 7th 2014

Vassiliki Papadimitrakopoulou, MD, provides an update on research into pembrolizumab (Keytruda) for the treatment of lung cancer.

Collaboration Accelerates KRAS Inhibitor Development

November 4th 2014

A novel first-in-class covalent KRAS inhibitor SML-8-73-1 has demonstrated promise in preclinical studies, prompting a 3-year research collaboration between the Dana-Farber Cancer Institute and Astellas Pharma Inc.

Expert Predicts the Future of Immune Therapies for Lung Cancer

November 1st 2014

Roy S. Herbst, MD, PhD, presented a top 10 list on immunotherapy in non-small cell lung cancer at the 2014 Multidisciplinary Symposium in Thoracic Oncology.

Dr. Patel on the Benefits of a Multidisciplinary Approach for Patients With Stage III Lung Cancer

November 1st 2014

Jyoti D. Patel, MD, thoracic oncologist, Northwestern University Feinberg School of Medicine, discusses the benefits of multidisciplinary approach for the treatment of patients with stage III disease.

Dr. Spigel Discusses Results from a Phase III Study Exploring Eribulin in NSCLC

November 1st 2014

David Spigel, MD, director of Lung Cancer Research at the Sarah Cannon Research Institute, discusses results from a phase III study exploring eribulin for the treatment of patients with non-small cell lung cancer.

Nivolumab Plus Chemotherapy Shows Similar Efficacy to Nivolumab Monotherapy in NSCLC

November 1st 2014

Nivolumab combined with platinum-based doublet chemotherapy achieved a manageable safety profile with clinical efficacy that was similar to single-agent nivolumab in patients with advanced NSCLC.

Expert Advises on Managing Side Effects of Targeted Lung Cancer Therapies

November 1st 2014

Jyoti D. Patel, MD, provides insight into managing the toxicities associated with molecular therapies used to treat patients with lung cancers.